Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SHP465 in Children 4-5 Years with ADHD
NCT03327402Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Primary endpoints: Maximum Plasma Drug Concentration at Week 4, Trough Plasma Drug Concentration at Day 28 and 7 more. Started Mar 2018; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03327402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03327402.